Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy

Bibliographic Details
Main Author: Baptist Gallwitz
Format: Article
Language:English
Published: SAGE Publishing 2012-01-01
Series:Clinical Medicine Insights: Endocrinology and Diabetes
Online Access:http://la-press.com/linagliptina-novel-dipeptidyl-peptidase-inhibitor-for-type-2-diabetes--a2986
_version_ 1828443021130072064
author Baptist Gallwitz
author_facet Baptist Gallwitz
author_sort Baptist Gallwitz
collection DOAJ
first_indexed 2024-12-10T21:23:03Z
format Article
id doaj.art-8a2470828598476ca7bf8e6dbd642905
institution Directory Open Access Journal
issn 1179-5514
language English
last_indexed 2024-12-10T21:23:03Z
publishDate 2012-01-01
publisher SAGE Publishing
record_format Article
series Clinical Medicine Insights: Endocrinology and Diabetes
spelling doaj.art-8a2470828598476ca7bf8e6dbd6429052022-12-22T01:33:04ZengSAGE PublishingClinical Medicine Insights: Endocrinology and Diabetes1179-55142012-01-0120125111Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes TherapyBaptist Gallwitzhttp://la-press.com/linagliptina-novel-dipeptidyl-peptidase-inhibitor-for-type-2-diabetes--a2986
spellingShingle Baptist Gallwitz
Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
Clinical Medicine Insights: Endocrinology and Diabetes
title Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
title_full Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
title_fullStr Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
title_full_unstemmed Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
title_short Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
title_sort linagliptin a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy
url http://la-press.com/linagliptina-novel-dipeptidyl-peptidase-inhibitor-for-type-2-diabetes--a2986
work_keys_str_mv AT baptistgallwitz linagliptinanoveldipeptidylpeptidaseinhibitorfortype2diabetestherapy